Global Influenza Vaccines Research Analysis Report 2023: A Potential $10.9 Billion market by 2030 - Expanding Manufacturing Capabilities and Focus on

The research website ResearchAndMarkets.com has included the "Forecast to 2030" report, which focuses on the global market for influenza vaccines. This report provides valuable information on the number of individuals vaccinated, an analysis of key companies, profiles of emerging players, promising vaccines currently in clinical development, the market's size and share, ongoing trends, significant deals, and recent developments.

According to estimates, the worldwide market for flu vaccines is expected to achieve a value of $10.9 billion by the year 2030.

The Centers for Disease Control and Prevention (CDC) suggests regular yearly flu shots for everyone aged 6 months and older. According to the World Health Organization (WHO), there are approximately 3 to 5 million instances of severe flu infections worldwide each year, resulting in 290,000 to 650,000 deaths related to the flu.

The large number of people living in emerging markets, coupled with low vaccination rates, the arrival of new vaccines, increased government backing for immunization, and a growing understanding of the importance of influenza vaccines for disease prevention are key factors that will propel the market for influenza vaccines.

The market for influenza vaccines is expected to grow in the coming years due to the growing investments in research and development by top companies like Sanofi, CSL Limited, and GlaxoSmithKline. These companies are investing in expanding their manufacturing capacities and are also focused on introducing new vaccines.

Nevertheless, the limited availability of vaccines caused by the diverse genetic variations of the viral strains is increasing the demand for vaccine updates from manufacturers on an annual basis. This obstacle significantly hinders the expansion of the market.

In July of 2023, Sinovac Biotech Ltd. disclosed a partnership with PT Bio Farma, a biopharmaceutical company owned by the Indonesian government. This alliance aims to cater to Indonesia's local vaccine market as well as the global market.

In November of 2022, researchers from the University of Pennsylvania made a significant breakthrough by creating a flu vaccine using a type of genetic material called mRNA. This vaccine was specifically designed to target and protect against various subtypes of the flu virus, totaling up to 20 different strains. The primary aim of this development was to enhance our defenses against potential future flu pandemics.

In October 2022, Novavax revealed encouraging outcomes from the Phase 1/2 clinical examination of its COVID-19-Influenza Blend (CIC) immunization contender.

In March of next year, the Australian authorities allocated over $100 million from their budget to safeguard vulnerable individuals through the seasonal flu vaccination.

Regional Analysis: Key Insights into the Influenza Vaccines Market and Predictions

In terms of geography, the influenza vaccine market in North America holds the predominant position, accounting for more than half of the market share in the year 2022.

In the continent of Europe, nearly every country has established national and/or regional plans or approaches for dealing with seasonal flu through vaccination.

The demand for influenza vaccines is anticipated to skyrocket in Asia due to several factors. Firstly, the Asian countries are experiencing rapid population growth, which directly contributes to the increasing need for healthcare services. Additionally, governments in Asia are prioritizing the improvement of healthcare facilities, leading to a more concentrated effort in combating diseases like seasonal influenza. Moreover, the incidence of seasonal influenza is on the rise, prompting individuals to seek protection through vaccines. Lastly, the growing disposable income in Asia allows for a greater affordability of influenza vaccines, further driving the market's growth in the region.

The Australasia region had the smallest portion of the influenza vaccines market in 2022.

By Nation: Market and Prediction of Influenza Vaccines - Important Observations

In terms of individual nations, the United States has obtained the largest portion of the market for influenza vaccines.

Japan ranks as the second biggest market for influenza vaccines.

In addition to the United States, influenza vaccines are also in high demand in China, Brazil, Canada, Australia, Germany, the United Kingdom, and India.

Poland has one of the smallest percentages of people getting vaccinated against influenza among the member countries of the European Union.

From: Company Subject: Insights into the Influenza Vaccines Market and Forecast Here are the main points you need to know: 1. The influenza vaccines market is predicted to experience substantial growth in the coming years. 2. Increasing awareness about the significance of vaccination and the rising incidence of influenza are driving this growth. 3. The market is expected to witness a surge in demand due to the ongoing COVID-19 pandemic, as people become more conscious of the need for preventive measures. 4. High prevalence of influenza in high-risk populations such as the elderly and children further contributes to the market's growth potential. 5. Key players in the industry are investing heavily in research and development to create more effective and efficient influenza vaccines. In summary, the influenza vaccines market is poised for significant expansion due to various factors, including increasing awareness, rising incidence, and the impact of the COVID-19 pandemic. As the market continues to grow, companies are actively working towards developing better vaccines to combat this widespread infectious disease.

In the year 2022, there was a 5% increase in sales of influenza vaccines by GlaxoSmithKline plc compared to the previous year.

Sales of AstraZeneca's flu vaccines experienced a 31% drop in 2022 due to the delayed onset of the flu season in Europe.

During September of 2022, Pfizer Inc. commenced the phase 3 clinical trial for an influenza vaccine that utilizes mRNA technology. Approximately 25,000 adults residing in the United States, who are 18 years or older, were enlisted to participate in the study.

In the year 2021, there was a significant surge in sales of Seqirus influenza vaccines, with a remarkable growth of 37% compared to the previous year. This impressive increase can be attributed to the robust expansion of sales in seasonal influenza vaccines.

In October 2022, Novavax shared encouraging findings from the Phase 1/2 clinical examination of its vaccine candidate, which aims to combat both COVID-19 and influenza simultaneously.

Factors Fueling the Growth of the Global Influenza Vaccines Market

Evolution of Immunization Techniques

Vaccinations: The Most Economical Approach to Preventing Diseases

Advancements in Science and Technology

Increasing government backing for immunization has led to a surge in awareness and acceptance of influenza vaccines. The recognition of the importance of vaccination is on the rise, resulting in more people opting for flu shots.

Strong investments in research and development (R&D), coupled with promising candidates in the pipeline, will propel market expansion.

The hurdles faced in the worldwide market for influenza vaccines

The intricacy of the process involved in developing and approving vaccines hinders product progression.

Challenges in Achieving Maximum Utilization of Authorized Vaccines

Challenges for New Players in the Vaccines Industry

Shortening the Duration to Develop Vaccines

Difficulties Confronted by Medical Staff in Vaccination

Analysis of Major Companies in the Influenza Vaccines Market

Gamma Vaccines Pty Ltd is a company that specializes in vaccine development and production.

Hualan Bioengineering Company, Limited Hualan Bioengineering Co., Ltd is a leading biotech firm in China, specializing in the development and production of vaccines and biological products. With advanced technology and experienced researchers, we strive to provide high-quality and innovative healthcare solutions to combat various diseases. At Hualan Bioengineering, we understand the importance of vaccines in preventing and controlling infectious diseases. Therefore, we have established a state-of-the-art facility that adheres to stringent quality control measures and follows international standards. This ensures the safety and efficacy of our products, giving patients and healthcare professionals peace of mind. Our dedicated team of experts continuously explores new possibilities in the field of biotechnology, pushing the boundaries of scientific research. We prioritize the pursuit of excellence, constantly improving our manufacturing processes and investing in advanced equipment to deliver reliable and effective vaccines. We believe in the power of collaboration and have established strong partnerships with renowned research institutions and industry leaders worldwide. By combining our expertise and resources, we can accelerate the development of breakthrough vaccines and address global healthcare challenges more effectively. Furthermore, we are committed to promoting public health and raising awareness about the importance of immunization. Through extensive education campaigns and community outreach programs, we strive to improve vaccine coverage and ensure its accessibility to underserved populations. Hualan Bioengineering aims to be at the forefront of the biotech industry, driving innovation and making a positive impact on society. By prioritizing research and development, quality manufacturing, global collaborations, and public health initiatives, we are dedicated to improving the lives of people around the world through advanced healthcare solutions.

(This section discusses Mylan, now a part of Viatris.) Mylan, which is now under the umbrella of Viatris, has made significant strides in the pharmaceutical industry. With the merger, the company has expanded its reach and capabilities. Viatris continues to uphold Mylan's commitment to providing high-quality and affordable medications to patients worldwide. This collaboration has unlocked numerous opportunities for innovation and growth in the realm of healthcare. By combining their resources, expertise, and global networks, Mylan and Viatris aim to improve access to vital medicines and address various health challenges faced by communities globally. Under the new entity, Viatris remains dedicated to its mission of empowering people worldwide to live healthier at every stage of life. The company's diverse product portfolio encompasses a wide range of therapeutic areas, including generic and branded prescription medicines, over-the-counter products, and complex biologics. With a strong focus on research and development, Viatris continuously strives to bring forth new treatments that cater to unmet medical needs. By investing in cutting-edge technologies and fostering collaborations with healthcare professionals, the company seeks to deliver innovative and effective solutions that enhance patients' quality of life. Furthermore, Viatris actively engages with policymakers, advocacy groups, and stakeholders to shape health policies and create an environment conducive to better healthcare outcomes. By championing access to affordable medicines and promoting sustainable healthcare practices, Viatris aims to make a positive impact on global health. In summary, the merger between Mylan and Viatris has propelled the company to new heights in the pharmaceutical industry. With a shared vision of providing accessible and high-quality healthcare solutions, Viatris is committed to improving the well-being of individuals worldwide.

The Shanghai Institute of Biological Products is a company engaged in the field of biological products.

Profile of New and Upcoming Players in the Influenza Vaccines Market

Distribution of Influenza Vaccines by Country, Number of Individuals Vaccinated, and Predicted Future Trends

To gain further insights regarding this report, please visit the following website: https://www.researchandmarkets.com/r/luwplq

About ResearchAndMarkets.comResearchAndMarkets.com is the foremost provider of global market research reports and market information. We supply you with up-to-date information on markets around the world, both at the international and regional levels. Our focus includes key industries, top companies, emerging products, and the most recent trends.

Contact for Media: Research and Markets Senior Manager: Laura Wood Email: [email protected] To schedule a meeting during Eastern Standard Time, dial +1-917-300-0470 For free calls within the United States and Canada, dial +1-800-526-8630 To schedule a meeting during Greenwich Mean Time, dial +353-1-416-8900 Fax number for the United States: 646-607-1907 Fax number for outside of the United States: +353-1-481-1716

According to a report published by Research and Markets,